Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus.

BACKGROUND We compared two strategies for treating patients infected with multidrug-resistant human immunodeficiency virus (HIV). METHODS Patients with multidrug-resistant HIV and HIV RNA levels of more than 5000 copies per milliliter were randomly assigned to a four-month structured interruption of treatment followed by a change in antiretroviral regimen (treatment-interruption group) or to an immediate change in regimen (control group). Genotypic and phenotypic resistance testing was performed. Disease progression, death, and changes in genotypic resistance, CD4 cell counts, HIV RNA levels, and quality of life were assessed. RESULTS After a median follow-up of 11.6 months, disease progression or death occurred in 22 of the 138 patients in the treatment-interruption group and in 12 of the 132 patients in the control group (P=0.01), with a hazard ratio of 2.57 (95 percent confidence interval, 1.2 to 5.5) for the treatment-interruption group. There were eight deaths in each group. In the treatment-interruption group, the mutant HIV populations completely or partially reverted to wild type by four months in 64.0 percent of patients. As compared with the control group, the treatment-interruption group had a mean CD4 cell count that was 85 cells per cubic millimeter lower from months 0 through 4 (P<0.001), 47 cells per cubic millimeter lower from months 5 through 8 (P<0.001), and 31 cells per cubic millimeter lower after eight months (P=0.11). The mean HIV RNA levels were 1.2 log copies per milliliter higher (on a base-10 scale) in the treatment-interruption group during months 0 through 4 (P<0.001), but they were not significantly different from those in the control group after month 4. The overall quality of life was similar in the two groups. CONCLUSIONS In patients infected with multidrug-resistant HIV, structured interruption of treatment was associated with greater progression of disease and did not confer immunologic or virologic benefits or improve the overall quality of life.

[1]  M. Mouroux,et al.  Re-occurrence of HIV-1 drug mutations after treatment re-initiation following interruption in patients with multiple treatment failure. , 2001, AIDS.

[2]  Michael Ames,et al.  A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy , 2002, AIDS.

[3]  P. Tebas,et al.  Effect of prolonged discontinuation of successful antiretroviral therapy on CD4+ T cell decline in human immunodeficiency virus-infected patients: implications for intermittent therapeutic strategies. , 2002, The Journal of infectious diseases.

[4]  Jeffrey N. Martin,et al.  Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia , 2002, AIDS.

[5]  A. Phillips,et al.  Changes in CD4 lymphocyte counts after interruption of therapy in patients with viral failure on protease inhibitor-containing regimens , 2000, AIDS.

[6]  K. Hertogs,et al.  Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure , 2000, AIDS.

[7]  J. Neaton,et al.  Experience with a cross‐study endpoint review committee for AIDS clinical trials , 1998, AIDS.

[8]  R Hoh,et al.  Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. , 2001, The New England journal of medicine.

[9]  R. Grant,et al.  Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. , 2000, The Journal of infectious diseases.

[10]  Terri Wrin,et al.  Persistence of drug-resistant HIV-1 after a structured treatment interruption and its impact on treatment response , 2003, AIDS.

[11]  K. Holmes,et al.  Guidelines for preventing opportunistic infections among HIV-infected persons--2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. , 2002, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[12]  P. Massip,et al.  Shift in HIV resistance genotype after treatment interruption and short-term antiviral effect following a new salvage regimen , 2000, AIDS.

[13]  M. Youle,et al.  Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. , 1999, AIDS.

[14]  M. Segal,et al.  Evolution of Phenotypic Drug Susceptibility and Viral Replication Capacity during Long-Term Virologic Failure of Protease Inhibitor Therapy in Human Immunodeficiency Virus-Infected Adults , 2002, Journal of Virology.

[15]  Robert W. Shafer,et al.  Evolution of Primary Protease Inhibitor Resistance Mutations during Protease Inhibitor Salvage Therapy , 2002, Antimicrobial Agents and Chemotherapy.